Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826-1832.

On page 1828 in the 20 March 2014 issue, there is an error in the text. In the second paragraph of the “Patients and treatment” section, the value “75%” should have read “74%.” The third sentence reads, “The median number of prior therapies was 5 (range, 1-13); all patients had received prior LEN and BORT, 99% had received prior DEX, 67% had received prior thalidomide, 75% had undergone prior stem cell transplantation, and 23% had received prior carfilzomib (CFZ).” The sentence should have read, “The median number of prior therapies was 5 (range, 1-13); all patients had received prior LEN and BORT, 99% had received prior DEX, 67% had received prior thalidomide, 74% had undergone prior stem cell transplantation, and 23% had received prior carfilzomib (CFZ).”

Also on page 1828, there are errors in Table 1. In the row “Stem cell transplantation,” the entries corresponding to the columns “POM+LoDEX” and “Total” read “74” and “75.” They should have read “72” and “74,” respectively. The corrected Table 1 is shown.

On page 1829, there are errors in the text. In the “LEN as last prior therapy” section, the values “6.2” and “8.4” should have read “6.5” and “11.4,” respectively. The third sentence reads, “The median response duration was 6.2 months with POM+LoDEX and 8.4 months with POM alone, and the median OS was 16.6 and 8.5 months, respectively (HR = 0.71, 95% CI = 0.42-1.21, P = .205).” The sentence should have read, “The median response duration was 6.5 months with POM+LoDEX and 11.4 months with POM alone, and the median OS was 16.6 and 8.5 months, respectively (HR = 0.71, 95% CI = 0.42-1.21, P = .205).”

On page 1831, there is an error in Table 3. In the row “Pyrexia,” the entry corresponding to “POM+LoDEX” reads “6.” It should have read “8.” The corrected Table 3 is shown.